The utility of the early intervention by the multi-disciplinary cooperation in the skin reaction due to EGFR inhibitor: Phase II study
Phase 2
- Conditions
- colorectal cancer, head and neck cancer
- Registration Number
- JPRN-UMIN000028286
- Lead Sponsor
- Wakayama Medical University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
The patients that an agreement was not obtained The patients who have difficulty in side effect monitoring
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severe skin reaction incidence
- Secondary Outcome Measures
Name Time Method utility of the episode of care sheet TTF Chemotherapy cancellation ratio due to the skin reaction
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by multi-disciplinary interventions in EGFR inhibitor-induced skin toxicity?
How does early multi-disciplinary care for EGFR inhibitor dermatitis compare to standard-of-care management in colorectal and head and neck cancer patients?
Which biomarkers predict severity of EGFR inhibitor-related skin reactions in JPRN-UMIN000028286 trial participants?
What adverse event management strategies are evaluated in Wakayama Medical University's EGFR inhibitor dermatitis trial?
How do combination approaches with EGFR inhibitors and dermatological interventions impact treatment adherence in oncology?